VIMKUNYA®▼ chikungunya vaccine

(recombinant, adsorbed)

Unite against chikungunya and help protect travellers from 12 years of age.

About VIMKUNYA®

VIMKUNYA® is indicated for active immunisation for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. This vaccine should be used in accordance with official recommendations.1

As with any vaccine, it is recommended to continue personal protection measures against mosquito bites after vaccination.1

VIMKUNYA®: grow your travel health offering and help protect those from 12 years against chikungunya*1

For around 2 in 5 people infected, chikungunya can leave lasting and debilitating effects.2,3 And with no specific treatment against the virus,4 helping protect people travelling to at-risk areas against infection is especially important.


Over 3 million visits were made by British Travellers to areas of substantial, recent chikungunya risk in 20235,6

India: 1.9 million

Mexico: 530,000

Thailand: 500,000

Indonesia: 335,000

Vimkunya

VIMKUNYA® is the first and only VLP, single-dose chikungunya vaccine approved in the UK1,7

Thanks to proven technology, virus-like particle (VLP) vaccines offer robust immune protection with favourable safety profiles and very few contradictions for their use.8–13

  • Proven VLP technology

    VLPs in VIMKUNYA® cannot replicate, or infect cells1

  • For a broad age range of travellers

    VIMKUNYA® can be given to individuals aged 12 years or older*1

  • Well-tolerated safety profile

    Assessed in two Phase 3 trials, including one specifically designed for individuals ≥65 years1,14,15

    No subjects in these trials with VIMKUNYA® developed serious treatment-related AEs†14,15

  • Rapid immunogenicity, with protective immunity at Day 22 (primary endpoint) starting to develop as early as 1 week after vaccination

    Respective seroconversion rates among individuals aged 12 to <65 years and ≥65 years: Day 22: 97.8% and 87.3%; Day 15: 96.8% and 82.3%; Day 8: 46.6% and not measured‡1,14,15

    So you can help protect even some last-minute travellers1,14–16

  • Easily administered

    A single intramuscular dose from a pre-filled syringe – with a long, 36-month refrigerated shelf life. 1,17

Help deliver protection against chikungunya with VIMKUNYA®,1 a simple addition to your travel health business.

1

A single dose from a pre-filled syringe.1

12+

VIMKUNYA® can be given to individuals aged 12 years or older.*1

VLP

VIMKUNYA® is the first and only VLP, single-dose chikungunya vaccine approved in the UK.1,7

≥65

Assessed in two Phase 3 trials, including one specifically designed for individuals ≥65 years.1,14,15

What are VLP vaccines, and how do they help to protect against viruses like chikungunya?


VLP vaccines contain proteins that assemble into VLPs to
mimic the virus without causing the disease…16,18

…resulting in very few contraindications for their use13

 

Anyone travelling to an at-risk area can catch chikungunya. With JCVI and NaTHNac advice now available, there is guidance to help you support traveller safety as they explore the world around them21,22

Read the JCVI guidance in full
This website is not owned or controlled by Bavarian Nordic

 

Choose VIMKUNYA® to help protect travellers…1,14,16

a

From individuals aged 12 and older

k

To the elderly enjoying retirement (aged ≥65)

k

And even some last-minute travellers needing protection§

 

a

Whether they’re diving into an unplanned, action-packed year abroad

k

Travelling for an important business engagement

a

Or jetting off for a fun-filled family adventure

 

With a well-tolerated vaccine that is easy to administer, you can help deliver protection against chikungunya‡1,14,15,17

Pivotal Trials

The immunogenicity and tolerability of VIMKUNYA have been assessed in two Phase 3 pivotal trials, including one specifically designed for individuals
≥65 years.14,15

ESBI-CV-317-004 (in adults and adolescents aged 12 to <65 years)

ESBI-CV-317-004 is a Phase 3, randomised, double-blind, placebo-controlled safety and immunogenicity trial of VIMKUNYA.14

In addition to evaluating safety, the following immunogenicity measures were assessed.14

Co-primary endpoints:14

  • Difference in chikungunya virus SNA seroresponse rate (vaccine minus placebo) at Day 22
  • Chikungunya virus SNA GMT at Day 22 for vaccine and placebo
  • Chikungunya virus SNA GMT ratio at Day 22 between all three pairs of vaccine lots (A:B, B:C, and A:C) in adults aged 18–45 years

Key secondary endpoint:14

  • Difference in chikungunya virus SNA seroresponse rate at Day 15, Day 183, and Day 8

Baseline characteristics¶14

Adapted from Richardson, et al. 2025

ESBI-CV-317-005 (in older adults ≥65 years)

ESBI-CV-317-005 is a Phase 3, randomised, double-blind, placebo-controlled safety and immunogenicity trial of VIMKUNYA.15

In addition to evaluating safety, the following immunogenicity measures were assessed.15

Co-primary endpoints:15

  • Difference in chikungunya virus SNA seroresponse rate (vaccine minus placebo) at Day 22
  • Chikungunya virus SNA GMT at Day 22 for the vaccine and placebo

Key secondary endpoint:15

  • Difference in chikungunya virus SNA seroresponse rates at Day 15 and Day 183

Baseline characterisitcs#15

Adapted from Tindale, et al. 2025

With a well-tolerated safety profile and no contraindications beyond hypersensitivity to the vaccine components, you can help protect travellers from 12 years against chikungunya.1,14,15

VIMKUNYA can help protect even some last-minute travellers.§1,14–16

Robust Immunogenicity

Protective immunity started to develop as soon as 1 week after vaccination with VIMKUNYA‡1,14,15

VIMKUNYA can help you protect people against chikungunya, including some last-minute travellers, as they discover the world around them.§1,14–16

Among adult and adolescent subjects aged 12 to <65 years:14

Adapted from Richardson, et al. 2025

Among older adult subjects aged ≥65 years:15

Adapted from Tindale, et al. 2025

 

12 to <65 years

Protective immunity started to develop as early as Week 1.‡14
Primary SNA endpoint at Day 22 met, with a robust GMT of 1618.1 (n=2,559) vs. 7.9 with placebo (n=424; p<0.0001).॥14

≥65 years

Protective immunity started to develop as early as Week 2.‡15
Primary SNA endpoint at Day 22 met, with a robust GMT of 723.9 (n=189) vs 8.1 with placebo (n=183; p<0.0001).15

Well-Tolerated

VIMKUNYA was well-tolerated, with mostly mild or moderate, self-limiting AEs1,14,15 

The safety and tolerability of VIMKUNYA have been evaluated in over 3,000 individuals,**across five clinical studies.1

No subjects in Phase 3 clinical trials with VIMKUNYA developed serious treatment-related AEs,† or serious AEs of special interest.**14,15

Adverse reactions reported in completed Phase 2 and 3 VIMKUNYA clinical trials1

aAdverse reactions reported are listed according to the following frequency: very common ≥ 1/10; common ≥ 1/100 to < 1/10; uncommon ≥ 1/1,000 to < 1/100; rare ≥ 1/10,000 to < 1/1,000; very rare < 1/10,000.1

Local and systemic adverse reactions reported in the Phase 3 clinical trials:

ESBI-CV-317-004: Adult and adolescent subjects (12 to <65 years)14

Adapted from Richardson, et al. 2025

ESBI-CV-317-005: Older adults (≥65 years)15

Adapted from Tindale, et al. 2025

 

Order Vimkunya®▼ Chikungunya vaccine (recombinant, adsorbed)

PIP CODE 4362067

Please note: Prices shown do not include any additional discounts and delivery charges you may be eligible for.

Find out more

Published date: 01 February 2026

Vimkunya® and its respective logo are registered trademarks of Bavarian Nordic A/S.

  1. VIMKUNYA (Chikungunya vaccine, recombinant, adsorbed), Summary of Product Characteristics.
  2. Rama K, et al. Clinical outcomes of chikungunya: A systematic literature review and meta-analysis. PLoS Negl Trop Dis. 2024;18(6):e0012254.
  3. Puntasecca CJ, et al. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
  4. Mourad O, et al. Chikungunya: An Emerging Public Health Concern. Curr Infect Dis Rep. 2022;24(12):217–228.
  5. Nurhayati-Wolff, H. Number of international visitor arrivals from the United Kingdom to Indonesia from 2014 to 2023. 2024. Accessed September 2025. Available at: https://www.statista.com/statistics/709662/number-of-international-visitor-arrivals-from-the-unitedkingdom-to-indonesia/#statisticContainer
  6. Office for National Statistics. Travel trends 2023. Travel trends estimates: UK residents visits abroad. October 2024. Accessed September 2025. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/ukresidentsvisitsabroad
  7. Ixchiq (chikungunya vaccine, live), Summary of Product Characteristics.
  8. Kjaer SK, et al. Clin Infect Dis. 2018;66(3):339–459.
  9. Mironova M, et al. Vaccines (Basel). 2024;12(4):439.
  10. Mohsen, MO, et al. Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022;19:993–1011.
  11. Dhawan M, et al. Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? 2023;9:100127.
  12. Gupta R, et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. 2023;14:1123805.
  13. Pollard AJ, et al. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100.
  14. Richardson JS, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025. DOI: 10.1016/S0140-6736(25)00345-9.
  15. Tindale LC, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025. DOI: 10.1016/S0140-6736(25)00372-1.
  16. Rosselot, G. Last-minute travellers. In CDC Yellow Book 2026: Health Information for International Travel. 2025. Accessed September 2025. Available at: https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/last-minute-travelers.html
  17. Benhamou D, et al. Assessing the Clinical, Economic, and Health Resource Utilization Impacts of Prefilled Syringes Versus Conventional Medication Administration Methods: Results From a Systematic Literature Review. Ann Pharmacother. 2023:10600280231212890.
  18. Nooraei S, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19(59).
  19. VIMKUNYA (chikungunya vaccine, recombinant), Prescribing Information.
  20. Tariq H, et al. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Front Microbiol. 2021;12:790121.
  21. Department of Health & Social Care. Chikungunya vaccine in UK travellers: JCVI advice. 2025. Accessed September 2025. Available at: https://www.gov.uk/government/publications/chikungunya-vaccine-for-uk-travellers-jcvi-advice-16-july-2025/chikungunya-vaccine-in-uk-travellers-jcvi-advice
  22. TravelHealthPro. Chikungunya. Assessed September 2025. Available at: https://travelhealthpro.org.uk/factsheet/27/chikungunya

VIMKUNYA®is indicated for active immunisation for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. This vaccine should be used in accordance with official recommendations.1

*VIMKUNYA® is contraindicated in individuals with hypersensitivity to the active ingredient or excipients. VIMVIMKUNYA®KUNYA has not been studied in pregnant or immunodeficient individuals, or those using systemic immunosuppressive therapies. Persons who are immunocompromised, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VIMKUNYA®. Decisions to administer VIMKUNYA®during pregnancy should take into account the individual’s risk of exposure to wild-type chikungunya virus, gestational age, and risks to the foetus or neonate. A risk to breastfed children cannot be excluded. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VIMKUNYA®and any potential adverse effects on the breastfed child from VIMKUNYA®.1

†One subject developed a serious AE considered possibly related to treatment (moderate detached retina of the eye). A causal relationship to VIMKUNYA® was unlikely but could not be ruled out definitively by the investigator; both the sponsor and the independent safety monitoring committee chair assessed this event as unrelated due to the subject seeing black spots pre-study.14

‡Seroresponse rate (considered the presumptive seroprotection rate) was defined as the percentage of subjects who achieved an anti-chikungunya SNA NT80 titre ≥100.1

§As defined by the World Health Organization, the last-minute traveller is anyone departing for an international destination on short notice, typically ≤2 weeks.16

¶Key exclusion criteria included: current pregnancy, breastfeeding, or plans to become pregnant during the trial; BMI 35 kg/m² or higher; history of any known congenital or acquired immunodeficiency; acute disease within 14 days; previous receipt of an investigational chikungunya virus vaccine or product; or any other medical condition that could adversely affect the participant’s involvement or the conduct of the trial.14 Full inclusion and exclusion criteria are provided in the Supplementary Appendix of Richardson, et al. 2025.

#Key exclusion criteria included: participation in another investigational clinical trial 30 days before day 1 or during the trial; previous receipt of any chikungunya virus vaccine; current HIV or hepatitis B or C infection; BMI of 35 kg/m² or higher; history of allergy to a component of the trial drug; history of any known immunodeficiency that could affect response to vaccination; moderate or severe acute disease; or any other medical condition that could adversely affect the participant’s involvement or the conduct of the trial.15 Full inclusion and exclusion criteria are provided in the Supplementary Appendix of Tindale, et al. 2025.

**3,141 received one 40 μg dose of VIMKUNYA® vaccine.1

††Serious adverse events of special interest defined as the occurrence of new onset or worsening of joint pain that is medically attended.14,15

॥All co-primary endpoints were met. The co-primary endpoint, assessing pairwise GMT ratios between consecutively manufactured VIMKUNYA® vaccine lots at Day 22, was achieved and demonstrated equivalence.14

Abbreviations:
AE, adverse event; CHIKV, chikungunya virus; DNA, deoxyribonucleic acid; GMT, geometric mean titre; JCVI, Joint Committee on Vaccination and Immunisation; LLOQ, lower limit of quantitation; Min, minimum; Max, maximum; N, total number of participants in the group; n, number of participants per parameter; NaTHNaC, National Travel Health Network and Centre; NT80, 80% neutralisation titre; SD, standard deviation; SNA, serum neutralising antibody; VLP, virus-like particle